Marshall Wace
AKTS icon

Marshall Wace’s Aktis Oncology AKTS Stock Holding History

Marshall Wace’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.35M Buy
+69,158
New +$1.68M ﹤0.01% 2042

Other funds holding AKTS

Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Merck & Co
Merck & Co Rahway, New Jersey $820M AUM 395.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $116B AUM 33.19% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Marshall Wace's AKTS Position: Q3 2026 in Review

Marshall Wace opened a new position in Aktis Oncology (AKTS) in Q3 2026: 69,158 shares worth $1.35M. The stake represents ﹤0.01% of the portfolio and ranks #2042 among its holdings.

76 funds tracked by Wall St. Rank hold AKTS as of Q3 2026.

  • Marshall Wace held 69,158 shares of Aktis Oncology worth $1.35M as of Q3 2026.
  • Aktis Oncology was a new Marshall Wace position in Q3 2026.
  • Aktis Oncology made up ﹤0.01% of Marshall Wace's portfolio in Q3 2026, its #2042 holding.
  • 76 funds tracked by Wall St. Rank held Aktis Oncology as of Q3 2026.

Based on Marshall Wace's 13F filing for Q3 2026, filed 13 Nov 2026.